JP2021501800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501800A5 JP2021501800A5 JP2020543732A JP2020543732A JP2021501800A5 JP 2021501800 A5 JP2021501800 A5 JP 2021501800A5 JP 2020543732 A JP2020543732 A JP 2020543732A JP 2020543732 A JP2020543732 A JP 2020543732A JP 2021501800 A5 JP2021501800 A5 JP 2021501800A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody drug
- drug conjugate
- administered
- cell lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023130793A JP2023154026A (ja) | 2017-11-01 | 2023-08-10 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580261P | 2017-11-01 | 2017-11-01 | |
| US62/580,261 | 2017-11-01 | ||
| US201862739635P | 2018-10-01 | 2018-10-01 | |
| US62/739,635 | 2018-10-01 | ||
| PCT/US2018/058613 WO2019089870A1 (en) | 2017-11-01 | 2018-11-01 | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023130793A Division JP2023154026A (ja) | 2017-11-01 | 2023-08-10 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501800A JP2021501800A (ja) | 2021-01-21 |
| JP2021501800A5 true JP2021501800A5 (https=) | 2021-12-09 |
Family
ID=64557131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543732A Withdrawn JP2021501800A (ja) | 2017-11-01 | 2018-11-01 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
| JP2023130793A Pending JP2023154026A (ja) | 2017-11-01 | 2023-08-10 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023130793A Pending JP2023154026A (ja) | 2017-11-01 | 2023-08-10 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220226439A1 (https=) |
| EP (1) | EP3703761A1 (https=) |
| JP (2) | JP2021501800A (https=) |
| KR (1) | KR20200080274A (https=) |
| CN (1) | CN111936170A (https=) |
| AU (1) | AU2018359546B2 (https=) |
| BR (1) | BR112020008375A2 (https=) |
| CA (1) | CA3080799A1 (https=) |
| IL (2) | IL315350A (https=) |
| MA (1) | MA50862A (https=) |
| MX (1) | MX2020004563A (https=) |
| SG (1) | SG11202003955UA (https=) |
| TW (1) | TW201922285A (https=) |
| WO (1) | WO2019089870A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| MX2021003734A (es) * | 2018-10-01 | 2021-07-16 | Seagen Inc | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. |
| MX2023006484A (es) * | 2020-12-03 | 2023-06-20 | Seagen Inc | Modulacion de la respuesta inmunitaria mediante conjugados anticuerpo-farmaco anti-cd30. |
| CN121752295A (zh) * | 2023-06-30 | 2026-03-27 | La生活产品有限责任公司 | 氧氮杂膦抗体药物缀合物及使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| CA3159253A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
-
2018
- 2018-11-01 WO PCT/US2018/058613 patent/WO2019089870A1/en not_active Ceased
- 2018-11-01 KR KR1020207014872A patent/KR20200080274A/ko not_active Ceased
- 2018-11-01 BR BR112020008375-5A patent/BR112020008375A2/pt unknown
- 2018-11-01 SG SG11202003955UA patent/SG11202003955UA/en unknown
- 2018-11-01 EP EP18811409.4A patent/EP3703761A1/en active Pending
- 2018-11-01 TW TW107138737A patent/TW201922285A/zh unknown
- 2018-11-01 CA CA3080799A patent/CA3080799A1/en active Pending
- 2018-11-01 MA MA050862A patent/MA50862A/fr unknown
- 2018-11-01 CN CN201880078567.7A patent/CN111936170A/zh active Pending
- 2018-11-01 IL IL315350A patent/IL315350A/en unknown
- 2018-11-01 AU AU2018359546A patent/AU2018359546B2/en active Active
- 2018-11-01 US US16/760,916 patent/US20220226439A1/en not_active Abandoned
- 2018-11-01 JP JP2020543732A patent/JP2021501800A/ja not_active Withdrawn
- 2018-11-01 MX MX2020004563A patent/MX2020004563A/es unknown
-
2020
- 2020-04-27 IL IL274277A patent/IL274277A/en unknown
-
2023
- 2023-08-10 JP JP2023130793A patent/JP2023154026A/ja active Pending
- 2023-08-14 US US18/449,591 patent/US20240245753A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501800A5 (https=) | ||
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| CN101686971B (zh) | 用于治疗多发性骨髓瘤的药物产品及其用途 | |
| JP2020002172A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2014515036A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| US20240307541A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| JP2021501776A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2020510039A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2021506817A5 (https=) | ||
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| RU2007134368A (ru) | Способы лечения лимфом с использованием сочетания химиотерапевтического средства и il-2, и, не обязательно, антител анти-cd20 | |
| JP2015529656A5 (https=) | ||
| JP2009538916A5 (https=) | ||
| JP2005529152A5 (https=) | ||
| JPWO2019183253A5 (https=) | ||
| JPWO2021138264A5 (https=) | ||
| JPWO2022117799A5 (https=) | ||
| JPWO2019217455A5 (https=) |